{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:15:04Z","timestamp":1788246904183,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.mayocp.2026.04.004","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:02:03Z","timestamp":1775840523000},"page":"1602-1614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hepatitis B Vaccine: Time to Rethink Our Correlate of Protection"],"prefix":"10.1016","volume":"101","author":[{"given":"Nawras","family":"Habash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Absah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.mayocp.2026.04.004_bib1","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","author":"Razavi-Shearer","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.mayocp.2026.04.004_bib2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.mayocp.2026.04.004_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/00333549231175548","article-title":"Progress and unfinished business: hepatitis B in the United States, 1980-2019","author":"Bixler","year":"2023","journal-title":"Public Health Rep"},{"issue":"13","key":"10.1016\/j.mayocp.2026.04.004_bib4","doi-asserted-by":"crossref","first-page":"477","DOI":"10.15585\/mmwr.mm7113a1","article-title":"Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022","volume":"71","author":"Weng","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.mayocp.2026.04.004_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections treatment guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"10.1016\/j.mayocp.2026.04.004_bib6","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/infdis\/jiab224","article-title":"Trends in prevalence and characteristics of resolved and current hepatitis B among US-born persons: National Health and Nutrition Examination Survey, 2001-2018","volume":"224","author":"Ly","year":"2021","journal-title":"J Infect Dis"},{"issue":"10381","key":"10.1016\/j.mayocp.2026.04.004_bib7","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2026.04.004_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"17","key":"10.1016\/j.mayocp.2026.04.004_bib9","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","article-title":"Genomic analysis of the host response to hepatitis B virus infection","volume":"101","author":"Wieland","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.mayocp.2026.04.004_bib10","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1073\/pnas.0308478100","article-title":"Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees","volume":"101","author":"Wieland","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.mayocp.2026.04.004_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-micro-092611-150203","article-title":"A virological view of innate immune recognition","volume":"66","author":"Iwasaki","year":"2012","journal-title":"Annu Rev Microbiol"},{"issue":"5","key":"10.1016\/j.mayocp.2026.04.004_bib12","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jhep.2016.12.024","article-title":"Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B","volume":"66","author":"Leboss\u00e9","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.04.004_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP2542","article-title":"New insights into how HBV manipulates the innate immune response to establish acute and persistent infection","volume":"18","author":"Revill","year":"2013","journal-title":"Antivir Ther"},{"issue":"8","key":"10.1016\/j.mayocp.2026.04.004_bib14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nri.2016.69","article-title":"Immune responses and immunopathology in acute and chronic viral hepatitis","volume":"16","author":"Shin","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.04.004_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis B virus infection","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.mayocp.2026.04.004_bib16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.mayocp.2026.04.004_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B\u2014report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","volume":"72","author":"Cornberg","year":"2020","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.mayocp.2026.04.004_bib18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2893.2010.01322.x","article-title":"Elimination of hepatitis B virus surface antigen and appearance of neutralizing antibodies in chronically infected patients without viral clearance","volume":"18","author":"Zhang","year":"2011","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.mayocp.2026.04.004_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.20411\/pai.v3i1.228","article-title":"ADCC-mediated CD56DIM NK cell responses are associated with early HBsAg clearance in acute HBV infection","volume":"3","author":"Yu","year":"2018","journal-title":"Pathog Immun"},{"issue":"4","key":"10.1016\/j.mayocp.2026.04.004_bib20","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mayocp.2026.04.004_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1063616","article-title":"Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection","volume":"13","author":"Yan","year":"2022","journal-title":"Front Microbiol"},{"issue":"10","key":"10.1016\/j.mayocp.2026.04.004_bib22","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1172\/JCI121957","article-title":"PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection","volume":"128","author":"Salimzadeh","year":"2018","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.mayocp.2026.04.004_bib23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","article-title":"End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN\u2013based therapy in patients with CHB","volume":"77","author":"Huang","year":"2022","journal-title":"J Hepatol"},{"issue":"5947","key":"10.1016\/j.mayocp.2026.04.004_bib25","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/307178a0","article-title":"Human hepatitis B vaccine from recombinant yeast","volume":"307","author":"McAleer","year":"1984","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.mayocp.2026.04.004_bib26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.15585\/mmwr.mm6905a5","article-title":"Licensure of a diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, haemophilus influenzae type b conjugate, and hepatitis B vaccine, and guidance for use in infants","volume":"69","author":"Oliver","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10161","key":"10.1016\/j.mayocp.2026.04.004_bib24","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","article-title":"Chronic hepatitis B virus infection","volume":"392","author":"Seto","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.mayocp.2026.04.004_bib27","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jvh.13125","article-title":"Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults","volume":"26","author":"Van Damme","year":"2019","journal-title":"J Viral Hepat"},{"issue":"12","key":"10.1016\/j.mayocp.2026.04.004_bib28","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.4254\/wjh.v7.i12.1660","article-title":"Induced immunity against hepatitis B virus","volume":"7","author":"Said","year":"2015","journal-title":"World J Hepatol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.04.004_bib29","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/vaccines13020184","article-title":"Immunosuppressive treatments and risk factors associated with non-response to hepatitis B vaccination: a cohort study","volume":"13","author":"Padilla-Matas","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.mayocp.2026.04.004_bib30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijid.2020.01.047","article-title":"Immune response to different types of hepatitis B vaccine booster doses 2-32 years after the primary immunization schedule and its influencing factors","volume":"93","author":"Zhao","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"4","key":"10.1016\/j.mayocp.2026.04.004_bib31","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/hep.32474","article-title":"Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose","volume":"76","author":"Bruce","year":"2022","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.mayocp.2026.04.004_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.70003","article-title":"Long-term immunity and anamnestic response following hepatitis B vaccination: a systematic review and meta-analysis","volume":"32","author":"Ramrakhiani","year":"2025","journal-title":"J Viral Hepat"},{"issue":"11","key":"10.1016\/j.mayocp.2026.04.004_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187661","article-title":"Durability of immunity by hepatitis B vaccine in Japanese health care workers depends on primary response titers and durations","volume":"12","author":"Yoshioka","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.mayocp.2026.04.004_bib34","doi-asserted-by":"crossref","DOI":"10.1017\/S0950268823001747","article-title":"Hepatitis B antibody levels after different doses of hepatitis B vaccination: a retrospective study based on hospitalized children","volume":"151","author":"Chai","year":"2023","journal-title":"Epidemiol Infect"},{"issue":"2","key":"10.1016\/j.mayocp.2026.04.004_bib35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/infdis\/jiw142","article-title":"A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen","volume":"214","author":"Simons","year":"2016","journal-title":"J Infect Dis"},{"issue":"15","key":"10.1016\/j.mayocp.2026.04.004_bib36","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1056\/NEJM198010093031501","article-title":"Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States","volume":"303","author":"Szmuness","year":"1980","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2026.04.004_bib37","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/hep.1840010502","article-title":"A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report","volume":"1","author":"Szmuness","year":"1981","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.mayocp.2026.04.004_bib38","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/0264-410X(96)00062-X","article-title":"Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination","volume":"14","author":"West","year":"1996","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.mayocp.2026.04.004_bib39","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/oxfordjournals.aje.a114061","article-title":"The control of hepatitis B virus infection with vaccine in Yupik Eskimos: demonstration of safety, immunogenicity, and efficacy under field conditions","volume":"121","author":"Heyward","year":"1985","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.04.004_bib40","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jama.2024.24490","article-title":"HepB-CpG vs HepB-alum vaccine in people with HIV and prior vaccine nonresponse: the BEe-HIVe randomized clinical trial","volume":"333","author":"Marks","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.mayocp.2026.04.004_bib41","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/infdis\/175.3.674","article-title":"Protection provided by hepatitis B vaccine in a Yupik Eskimo population\u2014results of a 10-year study","volume":"175","author":"Wainwright","year":"1997","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.mayocp.2026.04.004_bib42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.7326\/0003-4819-142-5-200503010-00008","article-title":"Antibody levels and protection after Hepatitis B vaccination: results of a 15-year follow-up","volume":"142","author":"McMahon","year":"2005","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.mayocp.2026.04.004_bib43","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/JCM.02430-07","article-title":"Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen","volume":"46","author":"Huzly","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mayocp.2026.04.004_bib44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcv.2016.12.002","article-title":"Diagnostic performance of serological assays for anti-HBs testing: results from a quality assessment program","volume":"87","author":"Raven","year":"2017","journal-title":"J Clin Virol"},{"key":"10.1016\/j.mayocp.2026.04.004_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2018.12.003","article-title":"Performance evaluation of the re-standardized Abbott Architect anti-HBs assay","volume":"111","author":"Wong","year":"2019","journal-title":"J Clin Virol"},{"issue":"3","key":"10.1016\/j.mayocp.2026.04.004_bib46","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/hepr.13470","article-title":"Discordance of hepatitis B vaccination policies for healthcare workers between the USA, the UK, and Germany","volume":"50","author":"Komatsu","year":"2020","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.mayocp.2026.04.004_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Recomm Rep"},{"issue":"7","key":"10.1016\/j.mayocp.2026.04.004_bib48","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3390\/vaccines12070710","article-title":"A comprehensive review of hepatitis B vaccine nonresponse and associated risk factors","volume":"12","author":"Tahir","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"27-28","key":"10.1016\/j.mayocp.2026.04.004_bib49","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1016\/j.vaccine.2004.02.046","article-title":"Most humoral non-responders to hepatitis B vaccines develop HBV-specific cellular immune responses","volume":"22","author":"Jarrosson","year":"2004","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.mayocp.2026.04.004_bib50","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.vaccine.2018.02.039","article-title":"Antibody response to hepatitis B vaccine is independently associated with hepatitis B breakthrough infection among adults: results from a three-year follow-up study in China","volume":"36","author":"Zhang","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.mayocp.2026.04.004_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae479","article-title":"Primary care guidance for providers who care for persons with human immunodeficiency virus: 2024 update by the HIV Medicine Association of the Infectious Diseases Society of America","author":"Horberg","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.mayocp.2026.04.004_bib52","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/jama.2025.9894","article-title":"HepB-CpG vaccine in people with HIV and prior nonresponse to HBV vaccine: the BEe-HIVe trial end-of-study results","volume":"334","author":"Marks","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mayocp.2026.04.004_bib53","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S1473-3099(19)30417-7","article-title":"Serological response to three alternative series of hepatitis B revaccination (Fendrix, Twinrix, and HBVaxPro-40) in healthy non-responders: a multicentre, open-label, randomised, controlled, superiority trial","volume":"20","author":"Raven","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"18","key":"10.1016\/j.mayocp.2026.04.004_bib54","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.vaccine.2018.03.044","article-title":"Monitoring the efficacy of infant hepatitis B vaccination and revaccination in 0- to 8-year-old children: protective anti-HBs levels and cellular immune responses","volume":"36","author":"Li","year":"2018","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.mayocp.2026.04.004_bib55","doi-asserted-by":"crossref","first-page":"e1500","DOI":"10.1542\/peds.2013-2940","article-title":"Duration of protection after infant hepatitis B vaccination series","volume":"133","author":"Middleman","year":"2014","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.mayocp.2026.04.004_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-00055-w","article-title":"Anti-HBs persistence and anamnestic response among medical interns vaccinated in infancy","volume":"15","author":"Hanafi","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.mayocp.2026.04.004_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127743","article-title":"A follow-up study on the protective efficacy and anamnestic response of recombinant CHO hepatitis B vaccine 26 years after immunization","volume":"64","author":"Kang","year":"2025","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.mayocp.2026.04.004_bib58","first-page":"893","article-title":"Serological assessment of hepatitis in patients with inflammatory bowel disease in Taiwan: a retrospective cohort analysis","volume":"15","author":"Lee","year":"2025","journal-title":"Life (Basel)"},{"issue":"6","key":"10.1016\/j.mayocp.2026.04.004_bib59","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00431-025-06221-6","article-title":"Evaluation of anti-HBs seropositivity rates in children with familial mediterranean fever","volume":"184","author":"Atamy\u0131ld\u0131z U\u00e7ar","year":"2025","journal-title":"Eur J Pediatr"},{"issue":"3","key":"10.1016\/j.mayocp.2026.04.004_bib60","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/MPG.0000000000003362","article-title":"Celiac disease-risk of hepatitis B infection","volume":"74","author":"Habash","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"11","key":"10.1016\/j.mayocp.2026.04.004_bib61","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1016\/j.cgh.2023.03.025","article-title":"Effectiveness of hepatitis B vaccination for patients with inflammatory bowel and celiac disease","volume":"21","author":"Ulrich","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.mayocp.2026.04.004_bib62","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/jmv.24506","article-title":"The efficacy of hepatitis B vaccination program in upper Egypt: flow cytometry and the evaluation of long term immunogenicity","volume":"88","author":"Makhlouf","year":"2016","journal-title":"J Med Virol"},{"issue":"5","key":"10.1016\/j.mayocp.2026.04.004_bib63","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.vaccine.2015.12.033","article-title":"Characteristics of immune memory 10-15 years after primary hepatitis B vaccination","volume":"34","author":"Brunskole Hummel","year":"2016","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.mayocp.2026.04.004_bib64","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561962618478X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561962618478X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:38:55Z","timestamp":1788244735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002561962618478X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":64,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S002561962618478X"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.04.004","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B Vaccine: Time to Rethink Our Correlate of Protection","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}